REVIEW PAPER
Albinism – symptomatology, aetiology, and therapy
1
Department of Medical Genetics, The Children’s Memorial Health Institute, Warsaw, Poland
Submission date: 2024-08-14
Final revision date: 2024-10-07
Acceptance date: 2024-10-07
Publication date: 2025-03-07
Corresponding author
Agnieszka Madej-Pilarczyk
Department of Medical Genetics, The Children’s Memorial Health Institute, Warsaw, Poland
Department of Medical Genetics, The Children’s Memorial Health Institute, Warsaw, Poland
Pediatr Pol 2025;61(1):60-65
KEYWORDS
TOPICS
ABSTRACT
Albinism is a rare, genetically determined disorder of melanogenesis resulting in a reduction or complete absence of melanin in tissues of ectodermal origin, especially skin, hair, and irises of the eyes. It may occur in isolated form as oculocutaneous albinism inherited in an autosomal recessive manner or ocular albinism inherited in an X-linked recessive manner. Syndromic forms of albinism may additionally include involvement of other systems with various combination of symptoms and signs. The paper presents the classification, clinical characteristics, pathogenesis, and genetic basis of various forms of isolated and syndromic albinism. The diagnostic approach and available therapeutic interventions have been discussed.
REFERENCES (46)
1.
Marçon CR, Maia M. Albinism: epidemiology, genetics, cutaneous characterization, psychosocial factors. An Bras Dermatol 2019; 94: 503-520.
2.
Brenner M, Hearing VJ. The protective role of melanin against UV damage in human skin. Photochem Photobiol 2008; 84: 539-549.
3.
Grønskov K, Ek J, Brondum-Nielsen K. Oculocutaneous albinism. Orphanet J Rare Dis 2007; 2: 43.
4.
Ma EZ, Zhou AE, Hoegler KM, et al. Oculocutaneous albinism: epidemiology, genetics, skin manifestation, and psychosocial issues. Arch Dermatol Res 2022, 315: 107-116.
5.
Kausar T, Bhatti MA, Ali M, et al. OCA5, a novel locus for non-syndromic oculocutaneous albinism, maps to chromosome 4q24. Clin Genet 2013; 84: 91-93.
6.
Balu K, Purohit. Mutational analysis of TYR gene and its structural consequences in OCA1A. Gene 2013; 513: 184-195.
7.
Lin S, Sanchez-Bretaño A, Leslie JS, et al. Evidence that the Ser192Tyr/Arg402Gln in cis Tyrosinase gene haplotype is a disease-causing allele in oculocutaneous albinism type 1B (OCA1B). NPJ Genom Med 2022; 7: 2.
9.
Hong ES, Zeeb H, Repacholi MH. Albinism in Africa as a public health issue. BMC Public Health. 2006; 6: 212.
10.
Kamaraj B, Purohit R. Mutational analysis of oculocutaneous albinism: a compact review. Biomed Res Int. 2014; 2014: 905472.
11.
Rooryck C, Morice-Picard F, Elcioglu NH, et al. Molecular diagnosis of oculocutaneous albinism: new mutations in the OCA1-4 genes and practical aspects. Pigment Cell Melanoma Res 2008; 21: 583e7.
12.
Inagaki K, Suzuki T, Shimizu H, et al. Oculocutaneous albinism type 4 is one of the most common types of albinism in Japan. Am J Hum Genet 2004; 74: 466e71.
13.
Tsang SH, Sharma T. X-linked ocular albinism. Adv Exp Med Biol 2018; 1085: 49-52.
14.
Lasseaux E, Plaisant C, Michaud V, et al. Molecular characterization of a series of 990 index patients with albinism. Pigment Cell Melanoma Res 2018; 31: 466-474.
15.
Kamaraj B, Purohit R. Mutational analysis of oculocutaneous albinism: a compact review. Biomed Res Int 2014; 2014: 905472.
16.
Kono M, Kondo T, Ito S, et al. Genotype analysis in a patient with oculocutaneous albinism 1 minimal pigment type. Br J Dermatol 2012; 166: 896-898.
17.
Toyofuku K, Valencia JC, Kushimoto T, et al. The etiology of oculocutaneous albinism (OCA) type II: the pink protein modulates the processing and transport of tyrosinase. Pigment Cell Res 2002; 15: 217-224.
18.
Toyofuku K, Wada I, Valencia JC, et al. Oculocutaneous albinism types 1 and 3 are ER retention diseases: mutation of tyrosinase or Tyrp1 can affect the processing of both mutant and wild-type proteins. FASEB J 2001; 15: 2149-2161.
19.
Boissy RE, Zhao H, Oetting WS, et al. Mutation in and lack of expression of tyrosinase-related protein-1 (TRP-1) in melanocytes from an individual with brown oculocutaneous albinism: a new subtype of albinism classified as “OCA3”. Am J Hum Genet 1996; 58: 1145-1156.
20.
Wei AH, Zang DJ, Zhang Z, et al. Exome sequencing identifies SLC24A5 as a candidate gene for nonsyndromic oculocutaneous albinism. J Invest Dermatol 2013; 133: 1834-1840.
21.
Grønskov K, Dooley CM, Østergaard E, et al. Mutations in C10orf11, a melanocyte-differentiation gene, cause autosomal- recessive albinism. Am J Hum Genet 2013; 92: 415-421.
22.
Volk AE, Hedergott A, Preisong M, et al. Biallelic mutations in L-dopachrome tautomerase (DCT) cause infantile nystagmus and oculocutaneous albinism. Hum Genet 2021; 140: 1157-1168.
23.
Pennamen P, Tingaud-Sequeira A, Gazova I, et al. Dopachrome tautomerase variants in patients with oculocutaneous albinism. Genet Med 2021; 23: 479-487.
24.
Schnur RE, Gao M, Wick PA, et al. OA1 mutations and deletions in X-linked ocular albinism. Am J Hum Genet 1998; 62: 800-809.
25.
De Vijlder HC, de Vijlder JJ, Neumann HA. Oculocutaneous albinism and skin cancer risk. J Eur Acad Dermatol Venereol 2013; 27: e433-434.
26.
Galli J, Loi E, Dusi L, et al. Oculocutaneous albinism: the neurological, behavioral, and neuro-ophthalmological perspective. Eur J Pediatr. 2023; 182: 2723-2733.
27.
Kutzbach BR, Summers CG, Holleschau AM, et al. Neurodevelopment in children with albinism. Ophthalmology 2008; 115: 1805-1808.
28.
Hong ES, Zeeb H, Repacholi MH. Albinism in Africa as a public health issue. BMC Public Health 2006; 6: 212.
29.
Oetting WS, Fryer JP, Shriram S, et al. Oculocutaneous albinism type 1: the last 100 years. Pigment Cell Res 2003; 16: 307-311.
30.
Kruijt CC, de Wit GC, Bergen AA, et al. The phenotypic spectrum of albinism. Ophthalmology 2018; 125: 1953-1960.
31.
Morimoto M, Nicoli ER, Kuptanon C, et al. Spectrum of LYST mutations in Chediak-Higashi syndrome: a report of novel variants and a comprehensive review of the literature. J Med Genet 2024; 61: 212-223.
32.
Khorram E, Tabatabaiefar MA, Yaghini O, et al.Griscelli syndrome type 1: a novel pathogenic variant, and review of literature. Mol Genet Genomics 2023; 298: 485-493.
33.
Montoliu L, Marks MS. A new type of syndromic albinism associated with mutations in AP3D1. Pigment Cell Melanoma Res 2017; 30: 5-7.
34.
Izumi K, Kohta T, Kimura Y, et al. Tietz syndrome: unique phenotype specific to mutations of MITF nuclear localization signal. Clin Genet 2008; 74: 93-95.
35.
Byrne S, Dionisi-Vici C, Smith L, et al. Vici syndrome: a review. Orphanet J Rare Dis 2016; 29:11: 21.
36.
Luque-Luna M, Borregan-Prats M, Lianes JG, Prat-Torres C. Waardenburg syndrome. Med Clin (Barc) 2024; 25: S0025-7753(24)00304-X.
37.
Chan KS, Bohnsack BL, Ing A, et al. Diagnostic yield of genetic testing for ocular and oculocutaneous albinism in a diverse United States pediatric population. Genes (Basel) 2023; 14: 135.
38.
Okamura K, Hayashi M, Abe Y, et al. NGS-based targeted resequencing identified rare subtypes of albinism: providing accurate molecular diagnosis for Japanese patients with albinism. Pigment Cell Melanoma Res 2019; 32: 848-853.
39.
Luo D, Linpeng S, Zeng L, et al. Molecular genetic study of 59 Chinese Oculocutaneous albinism families. Eur J Med Genet 2019; 62: 103709.
40.
Zuhlke Ch, Crie C, Gemoll T, et al. Polymorphisms in the genes for oculocutaneous albinism type 1 and type 4 in the German population. Pigment Cell Res 2007; 20: 225-227.
41.
Oetting WS, Pietsch J, Brott MJ, et al. The R402Q tyrosinase variant does not cause autosomal recessive ocular albinism. Am J Med Genet A 2009; 149A: 466-469.
42.
Oetting WS, King RA. Molecular basis of albinism: Mutations and polymorphisms of pigmentation genes associated with albinism. Human Mutation 1999; 13: 99-115.
43.
Liu S, Kuht HJ, Moon EH, et al. Current and emerging treatments for albinism. Surv Ophthalmol 2021; 66: 362-377.
44.
Davis PL, Baker RS, Piccione RJ. Large recession nystagmus surgery in albinos: effect on acuity. J Pediatr Ophthalmol Strabismus 1997; 34: 279-283.
45.
Adams DR, Menezes S, Jauregui R, et al. One-year pilot study on the effects of nitisinone on melanin in patients with OCA-1B. JCI Insight 2019; 4: e124387.
46.
Surace EM, Domenici L, Cortese K, et al. Amelioration of both functional and morphological abnormalities in the retina of a mouse model of ocular albinism following AAV-mediated gene transfer. Mol Ther 2005; 12: 652e8.
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
